AHRQ Tech Assessment Supports Primary Prevention Implantable Defibrillators
This article was originally published in The Gray Sheet
Executive Summary
The agency affirms the evidence in favor of implantable defibrillators for primary prevention of sudden cardiac death is strong for patients with reduced left-ventricular ejection fraction, but does not support resynchronization ICDs for this population.
You may also be interested in...
Richard Kronick Appointed As Next AHRQ Director
Kronick moves to the head of the Agency for Healthcare Research and Quality, replacing Carolyn Clancy, after serving as deputy assistant secretary for planning and evaluation at HHS since January 2010.
CMS Issues List Of Potential National Coverage Determination Topics
Most of the 33 items or services in the list have implications for manufacturers of medical devices, combination products or diagnostics.
ICD Scrutiny: Study Quantifies Significant Off-Guideline Implant Activity
The implantable defibrillator sector took another potential hit last week with findings that more than 20% of patients treated with the devices for primary prevention of sudden cardiac death should not receive them under current guidelines.